COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Exploratory Study of Tipranavir and Ritonavir in Multiple Protease Inhibitor-experienced HIV Patients

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT02238314
Recruitment Status : Completed
First Posted : September 12, 2014
Last Update Posted : September 12, 2014
Information provided by (Responsible Party):
Boehringer Ingelheim

Brief Summary:
The primary objective was to evaluate the antiviral activity and safety of two regimens of tipranavir (500 mg BID or 1000 mg BID) plus ritonavir (100 mg BID) administered in combination with 1 new nucleoside reverse transcriptase inhibitor (NRTI) + efavirenz in multiple protease-inhibitor-experienced HIV-1 positive patients.

Condition or disease Intervention/treatment Phase
HIV Infections Drug: Tipranavir low dose Drug: Tipranavir high dose Drug: Ritonavir Drug: Nucleoside Reverse Transcriptase Inhibitor (NRTI) Drug: Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI) Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 41 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Tipranavir Disodium: An Open-Label ExploratorySstudy of Tipranavir and Ritonavir in Combination With One Nucleoside Reverse Transcriptase Inhibitor and One Non-Nucleoside Reverse Transcriptase Inhibitor in Multiple Protease Inhibitor-Experienced HIV Patients
Study Start Date : January 1999
Actual Primary Completion Date : August 2001

Resource links provided by the National Library of Medicine

MedlinePlus related topics: HIV/AIDS

Arm Intervention/treatment
Experimental: Tipranavir low dose Drug: Tipranavir low dose
Drug: Ritonavir
Drug: Nucleoside Reverse Transcriptase Inhibitor (NRTI)
Drug: Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI)
Experimental: Tipranavir high dose Drug: Tipranavir high dose
Drug: Ritonavir
Drug: Nucleoside Reverse Transcriptase Inhibitor (NRTI)
Drug: Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI)

Primary Outcome Measures :
  1. Change from baseline in HIV-1 RNA concentrations [ Time Frame: weeks 16, 24, 48 and 80 ]
  2. Occurrence of HIV-1 RNA levels below the limit of quantitation (BLQ) (400 copies/mL) [ Time Frame: up to 112 weeks ]
    measured by the Roche Amplicor HIV-1 Monitor™ polymerase chain reaction (PCR) Method

  3. Occurrence of HIV-1 RNA levels BLQ (50 copies/mL) [ Time Frame: up to 112 weeks ]
    measured by the Roche Amplicor UltraSensitive™ PCR Method

  4. Number of patients with treatment-emergent and drug-related adverse events (AEs) [ Time Frame: up to 115 weeks ]
  5. Number of patients with serious adverse events (SAEs) [ Time Frame: up to 115 weeks ]
  6. Number of patients with grade 3 and 4 laboratory abnormalities [ Time Frame: up to 115 weeks ]

Secondary Outcome Measures :
  1. Change from baseline in cluster of differentiation (CD) 4+ cell count responses [ Time Frame: weeks 24, 48 and 80 ]
  2. Change from baseline in CD8+ cell count responses [ Time Frame: weeks 24, 48 and 80 ]
  3. Time to new or recurring AIDS-defining illness [ Time Frame: up to 115 weeks ]
  4. Time to new or recurring HIV-related illness [ Time Frame: up to 115 weeks ]
  5. Time to death [ Time Frame: up to 115 weeks ]
  6. Occurrence of AIDS-defining illness, [ Time Frame: up to 115 weeks ]
  7. Occurrence of HIV-related illness, [ Time Frame: up to 115 weeks ]
  8. Occurrence of death [ Time Frame: up to 115 weeks ]
  9. Time to virologic failure [ Time Frame: up to 115 weeks ]
    defined as plasma HIV-1 RNA values >400 copies/mL or a 0.5 log reduction from baseline at two consecutive time points

  10. Change from baseline in cholesterol [ Time Frame: up to 115 weeks ]
  11. Change from baseline in HDL [ Time Frame: up to 115 weeks ]
  12. Change from baseline in triglycerides [ Time Frame: up to 115 weeks ]
  13. Change from baseline in blood glucose [ Time Frame: up to 115 weeks ]
  14. Steady-state plasma concentrations [ Time Frame: up to week 24 ]
  15. Fold-change in concentration required to produce 50% of inhibition (IC 50) [ Time Frame: Baseline, weeks 24, 48 and 80 ]
    sequence-based HIV-1 analysis (genotyping) and drugs susceptibility assays (phenotyping)

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   13 Years and older   (Child, Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Multiple (two or more) PI-experience. Eligible patients must have had exposure to at least two antiretroviral regimens containing a single protease inhibitor or a regimen containing dual protease inhibitors
  • In the investigator's opinion, the patient had adhered to PI-containing regimens
  • Exposure of ≥ 3 months to the current PI therapy
  • Exposure of ≥ 4 months to the prior PI therapy with single PI-containing regimens
  • Stable PI-containing regimen for at least 2 months prior to study entry
  • HIV-1-RNA ≥ 5,000 copies/mL
  • Cluster of differentiation (CD)4+ cell count ≥ 50 cells/mm**3
  • At least one new NRTI option available
  • Age ≥ 13 years
  • Acceptable screening laboratory values that indicated adequate baseline organ function at the time of screening. Laboratory values were considered acceptable if the severity was ≤ Grade 1 (AIDS Clinical Trial Group (ACTG) Grading Scale). Stable Grade 2 abnormalities were permitted if the values had been demonstrated and documented for at least ≥ 2 months.
  • Acceptable medical history, physical examination, electrocardiogram, and chest X-ray prior to entry into the treatment phase of the study
  • Agreement to use a barrier contraceptive method of birth control for at least 30 days prior to study drug administration, during the study, and 30 days after the end of the study
  • Ability to swallow numerous tablets and capsules without difficulty
  • Ability to understand and provide informed consent. Minors were required to have approval of a parent or legal guardian

Exclusion Criteria:

  • Prior exposure, defined as > 7 treatment days, to nonnucleoside reverse transcriptase inhibitor (NNRTIs) including, but not limited to: nevirapine, efavirenz, delavirdine, atevirdine, MKC-442, loviride, and HBY-097
  • Clinically significant active or acute (onset within the month previous to study entry) medical problems, including the following: opportunistic infections, such as active cryptococcosis, Pneumocystis carinii pneumonia, herpes zoster, histoplasmosis, or cytomegalovirus or nonopportunistic diseases, including, but not limited to, progressive multifocal leukoencephalopathy, lymphoma, or malignancy requiring systemic therapy
  • Prior exposure (> 7 days) to tipranavir
  • History of clinically significant nervous system or muscle diseases, seizure disorder, or psychiatric disorder that might impair adherence to the protocol
  • Taking of any known P450 3A enzyme-inducing drugs within 30 days of study entry and including the following: rifabutin, rifampin, carbamazepine, dexamethasone, phenobarbital, phenytoin, sulfadimidine, sulfinpyrazone, or troleandomycin
  • Hypersensitivity to tipranavir and/or ritonavir
  • Use of interferons, interleukins, HIV vaccines, or any active immunizations within 30 days prior to study entry
  • Taking of any investigational medication with the exception of adefovir dipivoxil (Preveon™) and amprenavir (Agenerase™) within 30 days of study entry
  • Pregnancy or lactation (serum β-human chorionic gonadotrophin test had to have been negative within 14 days of study entry)
  • Evidence of active substance abuse, which in the investigator's opinion, could affect compliance to the protocol
  • In the investigator's judgment, inability to comply with the protocol requirements for reasons other than those specified
Additional Information:
Layout table for additonal information
Responsible Party: Boehringer Ingelheim Identifier: NCT02238314    
Other Study ID Numbers: 1182.2
First Posted: September 12, 2014    Key Record Dates
Last Update Posted: September 12, 2014
Last Verified: September 2014
Additional relevant MeSH terms:
Layout table for MeSH terms
HIV Infections
Lentivirus Infections
Retroviridae Infections
RNA Virus Infections
Virus Diseases
Sexually Transmitted Diseases, Viral
Sexually Transmitted Diseases
Immunologic Deficiency Syndromes
Immune System Diseases
Reverse Transcriptase Inhibitors
HIV Protease Inhibitors
Protease Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Anti-HIV Agents
Anti-Retroviral Agents
Antiviral Agents
Anti-Infective Agents
Cytochrome P-450 CYP3A Inhibitors
Cytochrome P-450 Enzyme Inhibitors
Nucleic Acid Synthesis Inhibitors